Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BADALAMENTI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.922
EU - Europa 8.010
AS - Asia 6.757
SA - Sud America 1.126
AF - Africa 235
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 14
Totale 30.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.703
SG - Singapore 2.658
RU - Federazione Russa 2.260
CN - Cina 1.598
IT - Italia 1.558
DE - Germania 943
BR - Brasile 925
FI - Finlandia 849
HK - Hong Kong 676
VN - Vietnam 638
UA - Ucraina 456
PL - Polonia 446
GB - Regno Unito 364
FR - Francia 317
JP - Giappone 247
IE - Irlanda 236
IN - India 166
BD - Bangladesh 159
KR - Corea 140
NL - Olanda 118
SE - Svezia 116
CA - Canada 102
IQ - Iraq 84
MX - Messico 73
AR - Argentina 68
AT - Austria 66
TR - Turchia 66
BE - Belgio 60
RO - Romania 58
ES - Italia 52
ZA - Sudafrica 51
MA - Marocco 41
IR - Iran 35
UZ - Uzbekistan 35
CI - Costa d'Avorio 31
PK - Pakistan 31
CL - Cile 29
ID - Indonesia 29
AU - Australia 28
EC - Ecuador 28
KE - Kenya 27
JO - Giordania 22
TN - Tunisia 22
VE - Venezuela 22
AE - Emirati Arabi Uniti 20
SA - Arabia Saudita 19
EG - Egitto 18
MY - Malesia 18
NP - Nepal 18
CO - Colombia 17
DZ - Algeria 17
LT - Lituania 15
BG - Bulgaria 14
KZ - Kazakistan 13
PH - Filippine 13
PY - Paraguay 13
AL - Albania 11
CH - Svizzera 11
CZ - Repubblica Ceca 11
JM - Giamaica 10
OM - Oman 10
UY - Uruguay 10
GR - Grecia 8
PE - Perù 8
EU - Europa 7
LB - Libano 7
AZ - Azerbaigian 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
BA - Bosnia-Erzegovina 5
BH - Bahrain 5
BY - Bielorussia 5
CR - Costa Rica 5
GE - Georgia 5
MD - Moldavia 5
MM - Myanmar 5
PA - Panama 5
CY - Cipro 4
DK - Danimarca 4
ET - Etiopia 4
IL - Israele 4
PT - Portogallo 4
SV - El Salvador 4
XK - ???statistics.table.value.countryCode.XK??? 4
AM - Armenia 3
AO - Angola 3
EE - Estonia 3
GH - Ghana 3
HN - Honduras 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
ML - Mali 3
MN - Mongolia 3
NO - Norvegia 3
PS - Palestinian Territory 3
SN - Senegal 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
KH - Cambogia 2
Totale 30.053
Salva come PNG Salva come JPEG
Città #
Ashburn 1.860
Singapore 1.652
Fairfield 1.369
San Jose 781
Chandler 744
Woodbridge 737
Houston 682
Hong Kong 645
Wilmington 600
Seattle 516
Ann Arbor 473
Cambridge 426
Moscow 417
Zgierz 377
Palermo 365
Council Bluffs 319
Beijing 284
Helsinki 272
Dallas 271
Jacksonville 247
Tokyo 238
Los Angeles 236
Medford 233
Dublin 229
Ho Chi Minh City 229
New York 225
Des Moines 201
Santa Clara 199
Frankfurt am Main 191
The Dalles 182
Lauterbourg 174
Boardman 166
Hefei 164
Hanoi 146
Princeton 144
Rome 132
Altamura 127
San Diego 123
Munich 114
Lawrence 112
Nanjing 109
Buffalo 107
São Paulo 106
Chicago 98
Ludwigshafen am Rhein 83
Orem 74
Dearborn 70
London 68
Tulsa 66
Milan 65
Nuremberg 61
Brussels 55
Seoul 55
Jinan 50
Warsaw 49
Lappeenranta 45
Changsha 44
Tianjin 44
Amsterdam 42
Montreal 39
Denver 38
Kitzingen 38
Nanchang 38
Atlanta 37
Phoenix 36
Rio de Janeiro 35
Shenyang 35
Bremen 34
Johannesburg 34
Vienna 34
Chennai 33
Guangzhou 32
Abidjan 31
Brooklyn 31
Baghdad 30
Haiphong 30
Da Nang 29
Hebei 28
Toronto 28
Kumar 26
Poplar 26
Manchester 25
San Francisco 25
Tashkent 25
Jiaxing 24
Pune 23
Turin 23
Falls Church 22
Nairobi 22
Amman 21
Columbus 21
Naples 21
Saint Petersburg 21
San Paolo di Civitate 21
Seongnam 21
Hangzhou 20
Mumbai 20
Redwood City 20
Erbil 19
Venice 19
Totale 19.028
Salva come PNG Salva come JPEG
Nome #
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic 402
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). 400
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 321
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 316
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 297
Founder mutations in BRCA1 and BRCA2 genes 295
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 289
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 282
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. 281
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 274
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 270
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 266
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers 259
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. 253
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma 253
Ductal lavage: a valid method of risk assessment and of early diagnosis in breast cancer. 252
A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. 252
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 252
Ductal lavage: a way of carefully tracing the breast-secreting duct 251
A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy 250
The role of Aurora-A inhibitors in cancer therapy. 246
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 245
Surgical Treatment of Extravasation Injuries 244
Dedifferentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report 240
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. 238
Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study 238
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 233
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 228
P16 ink4A, p53 alterations and S phase fraction are predictive of clinical outcome in laryngeal squamous cell carcinoma. 226
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience 226
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 225
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 225
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 224
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 223
Ductal Lavage: a valid method of risk assessment and of early diagnosis in breast cance 218
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 218
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 217
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 216
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 213
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 212
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases 211
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer 209
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors 209
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 209
Serum follistatin in patients with prostate cancer metastatic to the bone 206
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers 205
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 205
CT and MR imaging of chemotherapy-induced hepatopathy 204
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. 203
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 203
Fatal heart failure induced by pazopanib in a sarcoma patient previously treated with gemcitabine 203
PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy. 198
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 198
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 197
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 197
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 196
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options 195
Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study 195
Evaluation of predictive factors for i-CLARAS (intraoperative complications in laparoscopic renal and adrenal surgery): a multicentre international retrospective cohort study 194
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. 194
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 193
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 189
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 188
Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation 187
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 186
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond 185
A phase II study of Oxaliplatin Capecitabine chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 184
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 182
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 181
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation 180
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 178
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. 177
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 176
Cardiotossicità e Cardioprotezione. 176
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 175
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 174
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 173
Gists eredo familiari e pediatrici: aspetti biomolecolari e clinici. 172
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 172
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 171
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 171
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 171
Delaying surgery for patients with a previous SARS-CoV-2 infection 171
Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic 170
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 167
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 165
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study 165
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 161
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 159
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 158
Activin a and matrix metalloproteinase-2 and -9 blood levels as gauges of bone metastatic spread. In: Tumor microenvironment:Heterotypic interactions. 157
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 156
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 155
Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report 155
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 154
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer 153
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results 153
The use of somatostatin analogues in metastatic hormone refractory and chemo resistant prostate cancer with neuroendocrine differentiation. 151
PML down-regulation in soft tissue sarcomas 151
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 150
Totale 21.093
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.330
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.330
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021431 0 0 0 0 0 0 0 0 0 0 237 194
2021/20221.900 103 339 77 61 86 75 98 107 189 254 156 355
2022/20232.474 272 491 70 274 226 347 180 203 233 22 94 62
2023/20241.307 51 142 98 107 90 229 185 100 25 42 30 208
2024/20254.015 100 228 232 303 150 238 407 335 266 484 498 774
2025/202613.184 1.040 420 1.003 1.237 1.445 1.934 1.815 1.298 1.120 1.376 496 0
Totale 31.081